Abstract
The treatment landscape for advanced-stage Hodgkin lymphoma (HL) continues to evolve, with immune checkpoint inhibitors now pivotal to improving patient outcomes. One of the most promising developments is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This novel approach has demonstrated encouraging efficacy and is increasingly integrated into frontline treatment regimens. This article provides practical, evidence-based knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD. It reviews the most frequently observed adverse events, including immune-mediated events, and outlines best practices for monitoring and management. A real-world case study illustrates how proactive management and clinical judgment can influence outcomes in patients receiving nivolumab-AVD.
References
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., Lacouture, M. E., Masters, G. A., Naidoo, J., Nanni, M., Perales, M.-A., Puzanov, I., Santomasso, B. D., Shanbhag, S. P., Sharma, R.,...Ernstoff, M. S. (2021). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for ImmunoTherapy of Cancer, 9(6), e002435. https://doi.org/10.1136/jitc-2021-002435
Brice, P., de Kerviler, E., & Friedberg, J. W. (2021). Classical hodgkin lymphoma. The Lancet, 398(10310), 1518–1527. https://doi.org/10.1016/s0140-6736(20)32207-8
Bristol-Myers Squibb. (2025). Opdivo (nivolumab) package insert. https://packageinserts.bms.com/pi/pi_opdivo.pdf
Camp-Sorrell, D., Hawkins, R. A., & Cope, D. G. (2022). Clinical Manuel for the Oncology Advance Practice Nurse (4th ed ed.). https://ebookcentral.proquest.com/lib/mdanderson-ebooks/reader.action?docID=31291765&ppg=974
Cashen, A. F. (2024). The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1392653
Dash, A. (2024). Febrile neutropenic patients in hematological malignancies. In Critical Care Hematology (pp. 361–372). Springer Nature Singapore. https://doi.org/10.1007/978-981-97-5565-3_28
Herrera, A., LeBlanc, M., Castellino, S. M., Li, H., Rutherford, S. C., Evens, A. M., Davison, K., Punnett, A., Hodgson, D. C., Parsons, S. K., Ahmed, S., Casulo, C., Bartlett, N. L., Song, J. Y., Little, R. F., Kahl, B. S., Leonard, J., Kelly, K. M., Smith, S. M., & Friedberg, J. W. (2023). SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). Journal of Clinical Oncology, 41(17_suppl), LBA4–LBA4. https://doi.org/10.1200/jco.2023.41.17_suppl.lba4
Herrera, A. F., LeBlanc, M., Castellino, S. M., Li, H., Rutherford, S. C., Evens, A. M., Davison, K., Punnett, A., Parsons, S. K., Ahmed, S., Casulo, C., Bartlett, N. L., Tuscano, J. M., Mei, M. G., Hess, B. T., Jacobs, R., Saeed, H., Torka, P., Hu, B.,...Friedberg, J. W. (2024). Nivolumab+avd in advanced-stage classic Hodgkin’s lymphoma. New England Journal of Medicine, 391(15), 1379–1389. https://doi.org/10.1056/nejmoa2405888
Lai, C., Kandahari, A., & Ujjani, C. (2019). The evolving role of brentuximab vedotin in classical hodgkin lymphoma. Blood and Lymphatic Cancer: Targets and Therapy, 9, 63–71. https://doi.org/10.2147/blctt.s231821
Les, I., Martínez, M., Pérez-Francisco, I., Cabero, M., Teijeira, L., Arrazubi, V., Torrego, N., Campillo-Calatayud, A., Elejalde, I., Kochan, G., & Escors, D. (2023). Predictive biomarkers for checkpoint inhibitor immune-related adverse events. Cancers, 15(5), 1629. https://doi.org/10.3390/cancers15051629
Lu, M., Zhang, L., Li, Y., Wang, H., Guo, X., Zhou, J., Duan, L., Si, X., Xu, Y., & Zhang, L. (2020). Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. Thoracic Cancer, 11(3), 805–809. https://doi.org/10.1111/1759-7714.13313
Rutherford, S. C., Li, H., Herrera, A. F., Leblanc, M., Ahmed, S., Davison, K. L., Casulo, C., Bartlett, N. L., Tuscano, J. M., Hess, B., Torka, P., Kumar, P., Jacobs, R. W., Song, J. Y., Castellino, S. M., Kahl, B. S., Leonard, J. P., Smith, S. M., Friedberg, J. W., & Evens, A. M. (2023). Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged ≥60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826. Blood, 142(Supplement 1), 181. https://doi.org/10.1182/blood-2023-180114
Schneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Davies, M. J., Ernstoff, M. S., Fecher, L., Ghosh, M., Jaiyesimi, I., Mammen, J. S., Naing, A., Nastoupil, L. J., Phillips, T.,...Bollin, K. (2021). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. Journal of Clinical Oncology, 39(36), 4073–4126. https://doi.org/10.1200/jco.21.01440
Straus, D., Collins, G., Walewski, J., Zinzani, P., Grigg, A., Sureda, A., Illes, A., Kim, T., Alekseev, S., Specht, L., Buccheri, V., Younes, A., Connors, J., Forero-Torres, A., Fenton, K., Gautam, A., Purevjal, I., Liu, R., & Gallamini, A. (2020). Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Leukemia & Lymphoma, 61(12), 2931–2938. https://doi.org/10.1080/10428194.2020.1791846
Wijeratne, D., Wright, K., & Gyawali, B. (2021). Risk-stratifying treatment strategies for febrile neutropenia—tools, tools everywhere, and not a single one that works? JCO Oncology Practice, 17(11), 651–654. https://doi.org/10.1200/op.21.00148
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021). Endocrine toxicities of immune checkpoint inhibitors. Nature Reviews Endocrinology, 17(7), 389–399. https://doi.org/10.1038/s41574-021-00484-3
Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023). Immune-related adverse events of immune checkpoint inhibitors: A review. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1167975
